We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is now recommending a traditional approval pathway for development of antiretroviral drugs for HIV-1 infection, a major shift from the condensed process allowed since the epidemic was at its peak. Read More
A British charity is pledging roughly $154 million over the next five years toward research into treatments and diagnostics to improve cancer survival. Read More
The moment dietary supplement manufacturers start making specific curative claims, supplements are seen as drugs in the eyes of the FDA and require an IND, says a new guidance document. Read More
Drugmakers want the FDA to provide more details on how it would show regulatory flexibility to developers of drugs for rare diseases, saying recent draft guidance is unclear about what may or may not be appropriate. Read More
The European Medicines Agency announced a new drug pathway program that promises earlier, more extensive support for drugmakers researching new priority therapies to increase chances of taking them to market. Read More
A recent study published in JAMA Oncology found that lower income levels were linked to reduced participation in clinical trials for experimental cancer drugs. The results reinforce earlier findings from the same team, indicating that the disparity may be a trend and not an anomaly. Read More